Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified pharmacological treatment vs treatment as usual after first antipsychotic treatment failure in schizophrenia-spectrum disorders
2023-506602-39-00Phase 4Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised trial of clozapine in schizophrenia, schizoaffective disorder and schizophreniform disorder (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary endpoint: change in PANSS total score. Planned start Aug 2024; status: authorised.
02
Drugs
clozapine
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on 2023-506602-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506602-39-00.